2.28
+0.06(+2.70%)
Currency In USD
| Previous Close | 2.22 |
| Open | 2.2 |
| Day High | 2.28 |
| Day Low | 2.19 |
| 52-Week High | 9.37 |
| 52-Week Low | 1.31 |
| Volume | 172,292 |
| Average Volume | 2.71M |
| Market Cap | 94.04M |
| PE | -1.62 |
| EPS | -1.41 |
| Moving Average 50 Days | 1.88 |
| Moving Average 200 Days | 2.99 |
| Change | 0.06 |
If you invested $1000 in Pulmonx Corporation (LUNG) since IPO date, it would be worth $58 as of December 25, 2025 at a share price of $2.28. Whereas If you bought $1000 worth of Pulmonx Corporation (LUNG) shares 3 years ago, it would be worth $301.19 as of December 25, 2025 at a share price of $2.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Dec 03, 2025 9:05 PM GMT
REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on December 1, 2025 (the “Grant Date”),
Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025
GlobeNewswire Inc.
Oct 27, 2025 8:05 PM GMT
Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive OfficerDerrick Sung, former Pulmonx Chief Financial Officer, appointed Chief Operating Officer and Chief
Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025
GlobeNewswire Inc.
Oct 15, 2025 8:05 PM GMT
REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for t